kidney cancer

Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Fierce Pharma
Merck
Keytruda
kidney cancer
Pfizer
Inlyta
Sutent
Flag link:
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
Yahoo/Reuters
Merck KGaA
Bavencio
Pfizer
kidney cancer
Inlyta
Flag link:
Exelixis Gets the Patients Eventually
Exelixis Gets the Patients Eventually
Motley Fool
Exelixis
kidney cancer
renal cell carcinoma
Cabometyx
Flag link:
Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action
Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action
Fierce Pharma
Merck
Eisai
Lenvima
kidney cancer
thyroid cancer
Flag link:
Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer
Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
kidney cancer
Flag link:
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Fierce Pharma
Pfizer
renal cell carcinoma
kidney cancer
Inlyta
Flag link:
Novartis offloads failed cancer drug to Oncology Venture
Novartis offloads failed cancer drug to Oncology Venture
Fierce Biotech
Novartis
Oncology Venture
dovitinib
kidney cancer
cancer
Flag link:
Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data
Roche hails another PhIII win on Tecentriq combo, reports promising kidney cancer data
Endpoints
Roche
Tecentriq
kidney cancer
Flag link:
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
GoinPharma
Eisai
Merck
Bristol-Myers Squibb
kidney cancer
Keytruda
Lenvima
Opdivo
Flag link:
Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field
Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field
Fierce Pharma
Merck
Eisai
Keytruda
Lenvima
kidney cancer
Flag link:
Pfizer defends kidney-cancer position with Bavencio 'breakthrough'
Pfizer defends kidney-cancer position with Bavencio 'breakthrough'
Fierce Pharma
Pfizer
kidney cancer
Bavencio
Merck KGaA
Flag link:
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Pfizer, Exelixis cancer drugs get FDA approval for wider use
Reuters
Pfizer
Exelixis
Cabometyx
kidney cancer
Bosulif
blood cancer
Flag link:
Cancer Space Update: Label Expansion for Three Major Drugs
Cancer Space Update: Label Expansion for Three Major Drugs
Yahoo/Zacks.com
cancer
labeling
AstraZeneca
Faslodex
Pfizer
Sutent
kidney cancer
Roche
Gazyva
follicular lymphoma
Flag link:
Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer
Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
kidney cancer
Flag link:
Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales
Pfizer hits a snag in bid to jump-start Sutent's flagging kidney cancer sales
Fierce Pharma
Pfizer
Sutent
kidney cancer
Flag link:
Ipsen focuses on oncology to keep growing
Ipsen focuses on oncology to keep growing
GoInPharma
Ipsen
oncology
Xermelo
kidney cancer
Flag link:
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
Motley Fool
Exelixis
Bristol-Myers Squibb
kidney cancer
Cabometyx
Opdivo
Yervoy
Flag link:
Opdivo combo shows early survival benefit in kidney cancer
Opdivo combo shows early survival benefit in kidney cancer
BioPharma Dive
Opdivo
Yervoy
Bristol-Myers Squibb
kidney cancer
Flag link:
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Xconomy
Bristol-Myers Squibb
kidney cancer
Opdivo
Yervoy
Flag link:
Aveo soars as long-beleaguered cancer drug nears approval
Aveo soars as long-beleaguered cancer drug nears approval
Fierce Biotech
Aveo
Europe
tivozanib
kidney cancer
Flag link:

Pages